Gregg Vicky B 4

What Happened

• Vicky B. Gregg, a director of Quest Diagnostics (DGX), acquired 68 shares on April 20, 2026 as an award/acquisition (transaction code A). The shares were recorded at $194.70 each, for a total value of $13,239. This was an acquisition (not a sale), reflecting reinvestment rather than an open-market purchase.

Key Details

• Transaction date and price: April 20, 2026 — 68 shares at $194.70 per share.
• Reported value: $13,239.
• Shares owned after the transaction: not specified in this filing.
• Footnote: The filing states these shares were acquired under a dividend reinvestment plan administered by the reporting person's broker and are eligible for deferred reporting on Form 5; the insider elected to report the transaction early on this Form 4.
• Filing timeliness: Form 4 was filed April 24, 2026 (four days after the reported transaction). Form 4s are normally due within two business days, so this appears to be reported later than the standard deadline.

Context

• The transaction reflects dividend reinvestment (automatic purchase of additional shares using dividends), which is routine and doesn't necessarily signal a change in view by the insider.
• Purchases or acquisitions are generally more informative to investors than sales, but here the acquisition resulted from a DRIP rather than an intentional open‑market buy.